[go: up one dir, main page]

MA32711B1 - Pyrrolidine-2-carboxamides substitues - Google Patents

Pyrrolidine-2-carboxamides substitues

Info

Publication number
MA32711B1
MA32711B1 MA33771A MA33771A MA32711B1 MA 32711 B1 MA32711 B1 MA 32711B1 MA 33771 A MA33771 A MA 33771A MA 33771 A MA33771 A MA 33771A MA 32711 B1 MA32711 B1 MA 32711B1
Authority
MA
Morocco
Prior art keywords
pyrolidine
carboxamide substituted
compounds
carboxamide
substituted
Prior art date
Application number
MA33771A
Other languages
Arabic (ar)
English (en)
Inventor
Qingjie Ding
Nan Jiang
Jin-Jun Liu
Tina Morgan Ross
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32711B1 publication Critical patent/MA32711B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION PORTE SUR DES COMPOSÉS DE LA FORMULE (I) DANS LAQUELLE X, Y R1, R2, R3, R3, R4, R5, R6 ET R7, SONT TELS QUE DÉCRITS ICI ET DES ÉNANTIOMÈRES ET SELS PHARMACEUTIQUEMENT ACCEPTABLES ET ESTERS DE CEUX-CI. LES COMPOSÉS SONT UTILES EN TANT QU'AGENTS ANTI-CANCERS.
MA33771A 2008-09-18 2011-04-13 Pyrrolidine-2-carboxamides substitues MA32711B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9788408P 2008-09-18 2008-09-18
US22563309P 2009-07-15 2009-07-15
PCT/EP2009/061610 WO2010031713A1 (fr) 2008-09-18 2009-09-08 Pyrrolidine-2-carboxamides substitués

Publications (1)

Publication Number Publication Date
MA32711B1 true MA32711B1 (fr) 2011-10-02

Family

ID=41402151

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33771A MA32711B1 (fr) 2008-09-18 2011-04-13 Pyrrolidine-2-carboxamides substitues

Country Status (29)

Country Link
US (1) US20100075948A1 (fr)
EP (1) EP2340021B1 (fr)
JP (1) JP5658157B2 (fr)
KR (1) KR101380013B1 (fr)
CN (1) CN102159207B (fr)
AR (1) AR073598A1 (fr)
AU (1) AU2009294673B2 (fr)
BR (1) BRPI0919325A2 (fr)
CA (1) CA2734363C (fr)
CL (1) CL2011000589A1 (fr)
CO (1) CO6361910A2 (fr)
CR (1) CR20110099A (fr)
DK (1) DK2340021T3 (fr)
EC (1) ECSP11010898A (fr)
ES (1) ES2398342T3 (fr)
HR (1) HRP20130047T1 (fr)
IL (1) IL211167A0 (fr)
MA (1) MA32711B1 (fr)
MX (1) MX2011002976A (fr)
MY (1) MY160424A (fr)
NZ (1) NZ591024A (fr)
PE (1) PE20110367A1 (fr)
PL (1) PL2340021T3 (fr)
PT (1) PT2340021E (fr)
RS (1) RS52660B (fr)
RU (1) RU2506257C2 (fr)
TW (1) TWI367207B (fr)
WO (1) WO2010031713A1 (fr)
ZA (1) ZA201101740B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
CN101898998B (zh) * 2010-08-25 2012-09-19 武汉武药科技有限公司 一种盐酸替罗非班中间体的制备方法
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
WO2012076513A1 (fr) * 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag Dérivés de 3-cyano-1-hydroxyméthyl-2-phénylpyrrolidine en tant qu'inhibiteurs des interactions mdm2-p53 utiles pour le traitement de cancer
TWI494312B (zh) 2011-03-10 2015-08-01 Daiichi Sankyo Co Ltd 二螺吡咯啶衍生物
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101714856B1 (ko) * 2012-05-30 2017-03-09 에프. 호프만-라 로슈 아게 치환된 피롤리딘-2-카복스아미드
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (fr) 2013-02-28 2014-09-04 Amgen Inc. Inhibiteur mdm2 dérivé de l'acide benzoïque pour le traitement du cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
AU2014286237B2 (en) 2013-07-03 2020-08-20 F. Hoffmann-La Roche Ag mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
SG11201608667SA (en) 2014-04-17 2016-11-29 Univ Michigan Mdm2 inhibitors and therapeutic methods using the same
CA2976752C (fr) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Polytherapie pour traiter un cancer
KR20170134462A (ko) 2015-04-13 2017-12-06 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 btk 저해제의 병용 치료법
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
CN109843329A (zh) 2016-10-17 2019-06-04 第一三共株式会社 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法
KR102122469B1 (ko) * 2016-11-01 2020-06-12 주식회사 엘지화학 변성 공액디엔계 중합체 및 이의 제조방법
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
BR112020000553A2 (pt) 2017-07-11 2020-07-21 Vertex Pharmaceuticals Incorporated carboxamidas como moduladores de canal de sódio
WO2019213106A1 (fr) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Formes à l'état solide d'idasanutline
EP3860654B1 (fr) 2018-10-03 2025-06-25 Rijksuniversiteit Groningen Dérivés de nutline photosensibles et leurs utilisations
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
AU2020397059A1 (en) 2019-12-06 2022-07-21 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
CA2598690C (fr) * 2005-02-22 2011-11-15 The Regents Of The University Of Michigan Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
MX2009000285A (es) 2006-06-30 2009-06-08 Schering Corp Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.

Also Published As

Publication number Publication date
RU2011115111A (ru) 2012-10-27
HRP20130047T1 (hr) 2013-02-28
RS52660B (sr) 2013-06-28
MX2011002976A (es) 2011-04-11
CO6361910A2 (es) 2012-01-20
CA2734363A1 (fr) 2010-03-25
IL211167A0 (en) 2011-04-28
AU2009294673B2 (en) 2014-08-14
TWI367207B (en) 2012-07-01
PT2340021E (pt) 2013-01-25
EP2340021A1 (fr) 2011-07-06
PE20110367A1 (es) 2011-06-13
KR20110040989A (ko) 2011-04-20
BRPI0919325A2 (pt) 2021-03-30
PL2340021T3 (pl) 2013-04-30
TW201012798A (en) 2010-04-01
WO2010031713A1 (fr) 2010-03-25
JP5658157B2 (ja) 2015-01-21
AU2009294673A1 (en) 2010-03-25
CN102159207B (zh) 2015-02-04
US20100075948A1 (en) 2010-03-25
JP2012502940A (ja) 2012-02-02
MY160424A (en) 2017-03-15
RU2506257C2 (ru) 2014-02-10
KR101380013B1 (ko) 2014-04-10
CL2011000589A1 (es) 2011-08-12
ZA201101740B (en) 2013-08-28
DK2340021T3 (da) 2012-12-10
CR20110099A (es) 2011-04-04
ES2398342T3 (es) 2013-03-15
AR073598A1 (es) 2010-11-17
NZ591024A (en) 2013-01-25
CA2734363C (fr) 2016-10-25
CN102159207A (zh) 2011-08-17
ECSP11010898A (es) 2011-04-29
HK1160399A1 (en) 2012-08-17
EP2340021B1 (fr) 2012-11-07

Similar Documents

Publication Publication Date Title
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA31754B1 (fr) Cis-imidazolines chirales
MA31580B1 (fr) Derives de bicyclolactames substitués
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA29909B1 (fr) Derives de pyridazine
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA33528B1 (fr) Derives pyridin-4-yliques
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA31289B1 (fr) Derives de thiazolidine
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA31597B1 (fr) Nouveaux herbicides
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA31766B1 (fr) Composés organiques
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA31285B1 (fr) Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase